CA2572498A1 - Biphasic capsule formulation - Google Patents
Biphasic capsule formulation Download PDFInfo
- Publication number
- CA2572498A1 CA2572498A1 CA002572498A CA2572498A CA2572498A1 CA 2572498 A1 CA2572498 A1 CA 2572498A1 CA 002572498 A CA002572498 A CA 002572498A CA 2572498 A CA2572498 A CA 2572498A CA 2572498 A1 CA2572498 A1 CA 2572498A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical formulation
- release phase
- formulation according
- glyceride
- biphasic pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002051 biphasic effect Effects 0.000 title claims 7
- 239000007963 capsule composition Substances 0.000 title abstract 2
- 239000007787 solid Substances 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000005456 glyceride group Chemical group 0.000 claims 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- -1 fatty acid ester Chemical class 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract 5
- 238000009472 formulation Methods 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 230000004888 barrier function Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Capsule formulations are provided containing at least two different fill compositions which are prevented from mixing either by providing both of the fill compositions as solids or by providing a physical barrier which separates the fill compositions so that they are prevented from mixing. The invention has the advantage that two different formulations can be provided in a single capsule without one of the formulations having an adverse effect on the other.
Claims (6)
1. A biphasic pharmaceutical formulation comprising a solid rapid release phase and a solid sustained release phase, wherein said rapid release phase remains solid at a temperature below 30°C.
2. The biphasic pharmaceutical formulation according to claim 16, wherein the rapid release phase comprises a pharmaceutically active substance and a glyceride having a melting point above 30°C.
3. The biphasic pharmaceutical formulation according to claim 17, wherein the glyceride is a saturated polyglycolyzed glyceride.
4. The biphasic pharmaceutical formulation according to claim 17, wherein the glyceride is a hydrogenated fatty acid ester.
5. The biphasic pharmaceutical formulation according to claim 17, wherein the rapid release phase and the sustained release phase comprise a C12-C24 fatty acid.
6. The biphasic pharmaceutical formulation according to claim 20, wherein the C12-C24 fatty acid is oleic acid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9325445.6 | 1993-12-13 | ||
| GB939325445A GB9325445D0 (en) | 1993-12-13 | 1993-12-13 | Pharmaceutical formulations |
| CA002179041A CA2179041C (en) | 1993-12-13 | 1994-12-12 | Biphasic capsule formulation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002179041A Division CA2179041C (en) | 1993-12-13 | 1994-12-12 | Biphasic capsule formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2572498A1 true CA2572498A1 (en) | 1995-06-22 |
| CA2572498C CA2572498C (en) | 2010-07-13 |
Family
ID=37806595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2572498A Expired - Fee Related CA2572498C (en) | 1993-12-13 | 1994-12-12 | Biphasic capsule formulation |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2572498C (en) |
-
1994
- 1994-12-12 CA CA2572498A patent/CA2572498C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2572498C (en) | 2010-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL318560A1 (en) | Novel orally administered preparations containing cyclosporin of simple composition and high bioavailability | |
| CA2366754A1 (en) | Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants | |
| CA2185347A1 (en) | A carrier for hydrophobic drugs and a pharmaceutical composition based thereon | |
| HK1033263A1 (en) | Pharmaceutical compositions capable of being gelled | |
| CA2383036A1 (en) | Solid lipid formulations | |
| CA2376202A1 (en) | Novel preparation and administration form comprising an acid-labile active compound | |
| CA2466868A1 (en) | Oral capsule formulation with increased physical stability | |
| HUP0100970A2 (en) | Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent | |
| ATE152613T1 (en) | COMPOSITION WHICH FORMES A MICROEMULSION UPON PERORAL ADMINISTRATION | |
| NZ335685A (en) | Antiherpetic pharmaceutical compositions containing acyclovir for topical applicators | |
| CA2137764A1 (en) | Pharmaceutical compositions comprising solutions or dispersions of a staurosporine active ingredient in a saturated polyalkylene glycol glyceride | |
| CA2572498A1 (en) | Biphasic capsule formulation | |
| ATE324103T1 (en) | CONTROLLED RELEASE MEDICINAL PREPARATION CONTAINING TRAMADOL HYDROCHLORIDE | |
| CA2265815A1 (en) | Formulations for topical use | |
| CA2203566A1 (en) | Percutaneously administration preparation | |
| CA2197413C (en) | A pharmaceutical or veterinary composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |